Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endurox R4 Sports Drink Advertising Changes Recommended By NAD

This article was originally published in The Tan Sheet

Executive Summary

Future ads for PacificHealth Laboratories' Endurox R4 sports drink should explain performance claims and disclose on whom the products were tested, the National Advertising Division of the Council of Better Business Bureaus determines.

You may also be interested in...



PowerBar Perform Claims Supported By "General, Scientific Studies" - NAD

Advertising claims for PowerBar Perform and Perform Plus regarding the products' general effectiveness in aiding athletic performance are supported by "voluminous" data, according to the National Advertising Division of the Council of Better Business Bureaus.

PowerBar Perform Claims Supported By "General, Scientific Studies" - NAD

Advertising claims for PowerBar Perform and Perform Plus regarding the products' general effectiveness in aiding athletic performance are supported by "voluminous" data, according to the National Advertising Division of the Council of Better Business Bureaus.

PowerBar Perform Claims Supported By "General, Scientific Studies" - NAD

Advertising claims for PowerBar Perform and Perform Plus regarding the products' general effectiveness in aiding athletic performance are supported by "voluminous" data, according to the National Advertising Division of the Council of Better Business Bureaus.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel